Sort
53,477 grants matching “addiction”
OTHER FUNCTIONS: N01DA-14-7789 NIDA CENTER FOR GENETIC STUDIES TASK ORDER 2; FY14- POP 4/30/2014 - 4/29/2015.
$3,352,407Jay Tischfield · Rutgers, The State Univ Of N.J. · N01 · FY2018 · DA
HEAL ERN: Data Coordinating Resource Center
$3,350,650Kevin M Watt · University Of Utah · U24 · FY2024 · TR
Associative learning, decision-making, and addiction
$3,349,605Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2014 · DA
Preventing Parental Opioid and/or Methamphetamine Addiction within DHS-Involved Families: FAIR
$3,348,667Lisa Saldana · Oregon Social Learning Center, Inc. · UH3 · FY2020 · DA
STSS Aspire Heal Task Order 10
$3,347,069Axle Informatics, Llc · N01 · FY2023 · DA
Associative learning, decision-making, and addiction
$3,333,766Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2020 · DA
Support for Enhancement Excellence in Research at UPR RP
$3,332,244Rafael Arce Arce · University Of Puerto Rico Rio Piedras · S06 · FY2007 · GM
Center for the Assessment of the Public Health Impact of Tobacco Regulations
$3,331,356Rafael Meza · University Of Michigan At Ann Arbor · U54 · FY2018 · CA
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
$3,331,239Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2024 · DA
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems (FORTRESS)
$3,330,528Matthew Aalsma · Indiana University Indianapolis · R33 · FY2024 · DA
Integrative genetics of behavior with high throughput technologies
$3,330,318David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2009 · AA
PET Radiopharmaceutical Sciences
$3,330,051Victor W Pike · National Institute Of Mental Health · ZIA · FY2011 · MH
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
$3,329,591Joseph Grieco · Park Therapeutics, Inc. · UG3 · FY2023 · DA
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
$3,324,591Joseph Grieco · Park Therapeutics, Inc. · UG3 · FY2024 · DA
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
$3,323,278Daniel K Benjamin · Duke University · U24 · FY2024 · TR
Innovative modeling of the biopsychosocial model in animals: Validation of outcomes for assessing emotional and cognitive domains affected by naturally-occurring chronic pain in dogs
$3,320,159Margaret Elizabeth Gruen · North Carolina State University Raleigh · R01 · FY2024 · AR
Integrative genetics of behavior with high throughput technologies
$3,319,050David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2016 · AA
Implementing and Personalizing Best-In-Class Opioid-sparing Pain Management for Major Inpatient Surgeries in Children
$3,315,439Senthilkumar Sadhasivam · University Of Pittsburgh At Pittsburgh · U01 · FY2025 · HD
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal
$3,312,204Frances Rudnick Levin · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UG3 · FY2022 · DA
Deep sequencing studies for cannabis and stimulant dependence
$3,311,492Kirk C. Wilhelmsen · Univ Of North Carolina Chapel Hill · R01 · FY2010 · DA
HD2A Research Adoption Support Center (RASC)
$3,311,025Mark P. McGovern · Stanford University · U2C · FY2022 · DA
Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors
$3,303,010Kenner Rice · National Institute On Drug Abuse · ZIA · FY2024 · DA
Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD)
$3,300,824David A Smelson · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · MH
Sequential Trial of Adding Buprenorphine, Cognitive Behavioral Treatment, and Transcranial Magnetic Stimulation to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (ACTION)
$3,290,624Kelly S. Barth · Medical University Of South Carolina · R01 · FY2023 · DA
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder
$3,287,052Renee Lynn Shirley · Virogenomics Biodevelopment, Inc. · UG3 · FY2025 · DA